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The results show complementary strength of ANOVA-based and MCC-based approaches
for different biological purposes. For detecting biomarkers with concordant inter-class pat-
terns across studies, min-MCC has better power and performance. If biomarkers with
discordant inter-class patterns across studies are expected and are of biological interests,
ANOVA-maxP better serves this purpose.
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1.0 INTRODUCTION
Microarray technology provides an opportunity for global monitoring of gene expression ac-
tivities. As the technology matures and becomes prevalent in biomedical research, many
data sets have been accumulated in the public internet domain, for example the NCBI Gene
Expression Omnibus (Edgar et al., 2002), the EBI ArrayExpress (Parkinson et al., 2005)
and the Stanford Microarray Database (Sherlock et al., 2001). The development of effective
information integration of multiple microarray studies has gained increasing attention.
In this chapter, we will provide a brief introduction of the technology of microarray and
meta-analysis. Then, we will describe the progress of microarray meta-analysis for the past
decade.
1.1 THE PRINICIPLE AND TECHNOLOGY OF MICROARRAY
A microarry is a tool used to sift through and analyze the information contained within
a genome or proteome. It consists of different nucleic acid or protein probes, called fea-
tures, that are chemically attached to a substrate, which can be a microchip, a glass slide
or a microsphere-sized bead. It is a multiplex technology used in molecular biology and in
medicine. It can be a short section of a gene or other DNA element that are used as probes to
hybridize a cDNA or cRNA sample (called target) under high-stringency conditions. Probe-
target hybridization is usually detected and quantified by detection of fluorophore-, silver-, or
chemiluminescence-labeled targets to determine relative abundance of nucleic acid sequences
in the target. To summarize, we can say a microarray is a tool for analyzing gene expression
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that consists of a small membrane or glass slide containing samples of many genes arranged
in a regular pattern.
Why are microarrays important? Because they may contain a very large number of genes
and because of their small size. Therefore, microarrays are useful when an investigator wants
to survey a large number of genes quickly or when the sample to be studied is small. In addi-
tion, a microarray can be used to examine the expression of hundreds or thousands of genes
at once, which promises to revolutionize the way scientists examine gene expression. This
technololgy is still considered to be in its infancy; therefore, many initial studies using mi-
croarrays have represented simple surveys of gene expression profiles in a variety of cell types.
DNA microarrays can be used to measure changes in expression levels, to detect sin-
gle nucleotide polymorphisms (SNPs), in genotyping or in resequencing mutant genomes.
Microarrays also differ in fabrication, workings, accuracy, efficiency, and cost. Additional
factors for microarray experiments are the experimental design and the methods of analyzing
the data.
1.1.1 Technology of microarray
In standard microarrays, the probes are attached to a solid surface by a covalent bond to
a chemical matrix (via epoxy-silane, amino-silane, lysine, polyacrylamide or others). The
solid surface can be glass or a silicon chip, in which case they are commonly known as gene
chip or colloquially as an ”Affy chip” when an Affymetrix chip is used. Other microarray
platforms, such as Illumina, use microscopic beads, instead of the large solid support. DNA
arrays are different from other types of microarray only in that they either measure DNA or
use DNA as part of their detection system.
Microarray technology evolved from Southern blotting, where fragmented DNA is at-
tached to a substrate and then probed with a known gene or fragment. The use of a
collection of distinct DNAs in arrays for expression profiling was first described in 1987.
2
The arrayed DNAs were used to identify genes whose expression is modulated by interferon.
These early gene arrays were made by spotting cDNAs onto filter paper with a pin-spotting
device. The use of miniaturized microarrays for gene expression profiling was first reported
in 1995, and a complete eukaryotic genome (Saccharomyces cerevisiae) on a microarray was
published in 1997.
Arrays of DNA can be spatially arranged, as in the commonly known gene chip (also
called genome chip, DNA chip or gene array), or can be specific DNA sequences labelled
such that they can be independently identified in solution. The traditional solid-phase array
is a collection of microscopic DNA spots attached to a solid surface, such as glass, plastic or
silicon biochip. The affixed DNA segments are known as probes (although some sources use
different terms such as ”reporters”). Thousands of them can be placed in known locations
on a single DNA microarray.
DNA microarrays can be used to detect DNA (as in comparative genomic hybridization),
or detect RNA (most commonly as cDNA after reverse transcription) that may or may not
be translated into proteins. The process of measuring gene expression via cDNA is called
expression analysis or expression profiling.
Figure 1 shows the details of labeling and hybridization of microarrays. The left one is
for cDNA arrays and the right one is for Affymetrix Gene Chip.
3
Figure 1: How the micorarray technology works.
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1.1.2 Steps of a microarray experiment
The steps of a microarray experiment are as follows: experimental design, data standard-
ization image acquisition and analysis, data pre-processing and normalization, and various
statistical and data mining techniques to study data sets.
1. RNA is first isolated from different tissues via developmental stages, disease states or
samples subjected to appropriated treatments or extracted from different experimental
conditions.
2. The RNA is then labeled with two different fluorescent dyes and co-hybridized to a mi-
croarray that allows expression to be asseyed and compared between appropriate sample
pairs.
3. The array is then scanned to acquire fluorescent images. Independent gray scale TIFF
(Tagged Information File Format) images are generated for each pair of samples to be
compared.
4. These images must then be analyzed to identify arrayed spots and to measure the relative
fluorescence intensities for each element (dye). Low quality data is filtered out and the
remaining high quality data is normalized.
5. Finally depending on the aim of the sudy, one can infer satistical significance or differ-
ential expression, perform various exploratory data analyses, classify samples according
to their disease subtypes and carry pathway analysis.
Complete information from all the steps should be collected according to certain stan-
dards, such as the Minimum Information About a Microarray Experiment (MIAME) and
archived properly. Figure 2 is a flow chart for the steps of microarray experiments. For more
details, please refer to www.ebi.ac.uk/arrayexpress/Standards/index.html.
5
Figure 2: Steps of a microarray experiment.
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1.1.3 Types of microarrays
Several competing technologies for microarray probe implementation have been developed
over the past decade. We call them platforms. The existence of multiple technologies has
raised the possiblity of cross-platform comparison and integration of data. Table 1 shows
some comparisons among four major different platforms.
1.1.4 Steps of microarray analysis
Once we get data from a microarray experiment described in the previous section, the next
step is to do data analysis. The procedure for microarray data analysis is as follows:
1. Experimental design (Implementation):
Define the biological question and hypothesis clearly. Design the microarray experimental
scheme carefully; include biological replication in experimental design.
2. Data collection and archiving:
Compliance with microarray information collection standards (e.g. MIAME).
3. Image acquisition:
Avoid photo-bleaching. Try to balance the overall intensities between the two dyes and
scan images at appropriate resolution.
4. Image analysis:
Inspect the gridding result manually and adjust the mask and flag poor-quality spots if
necessary. Choose and apply appropriate aegmentation algorithm.
5. Data pre-processing:
Remove poor-quality spots with intensity by lowering the background plus two standard
deviations. Log-transform the intensity ratios.
6. Data normalization:
Use diagnositc plots to evaluate the data and consider a proper method for normalization.
7. Identifying differentially expressed genes:
Calculate a statistic based on the replicate array data for ranking genes. Select a cut-
off value for rejecting the null-hypothesis. Do not use a fixed threshold (i.e. two-fold
increase or decrease) to infer significance.
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Table 1: Comparison of four different major microarray platforms
Platform CodeLink Affymetrix Agilent cDNA
Array format 30-mer 25-mer 60-mer
Hybridization time 18h 16h 17h 17h
Hybridizaion temp 37oC 45oC 60oC 60oC
Colors One-color One-color One/Two color Two-color
Manufacturer GE company Affymetrix com-
pany
Agilent company Individual Labo-
ratory
Probe preparation 3-D aqueous
gel matrix
Probes are short
oligos synthesized
through a
photolighographic
approach
Probes are printed
by InKjet technol-
ogy form HP
Probes are usu-
ally amplified by
PCR and spot-
ted by root
Density ∼57000
probes
423500 probes 22000 probes Maximum of
∼15000 probes
Advantages Sensitivity; Reproducibility; Reproducibility; Inexpensive;
3D surface; Mature platform; Mature platform; Customization is
possible
Customization
is possible;
Customization; Customization
Disadvntages Non-contract
printing
Less sensitive Two-color bias Poor specificity
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8. Exploratory data analysis:
Use different analysis tools with different settings to ”explore” the data. Validate the
results by follow-up experiments.
9. Other down-stream analyses:
Do other down-stream analyses based on the differentially expressed genes, like clustering,
classfication, pathway analysis,...etc.
1.2 META-ANALYSIS
1.2.1 Basic ideas of meta-analysis
A meta-analysis is a statistical technique used to evaluate a pool of studies for systematic
reviews. Most often it is used to assess the clinical effectiveness of healthcare interventions
quantitatively and achieves this by combining data from two or more independent studies.
Glass (1976) defines meta-analysis as: The statistical analysis of a large collection of analysis
results for the purpose of integrating the findings.
The basic purpose of meta-analysis is to provide the same methodological rigor to a lit-
erature review that we require from experimental research. In other words, meta-anlyses are
generally centered on the relationship between one explanatory and one response variable.
This relationship, ”the effect of X and Y”, defines the analysis. So, meta-analysis provides
an opportunity for shared subjectivity in reviews, rather than true objectivity.
Karl Pearson performed the first meta-analysis in 1904. Pearson wanted to overcome
reduced statistical power in studies with small sample sizes. He analyzed the results from
a group of studies and concluded that a new piece of research could be created to allow for
more accuracy in analysis. Later, Tippett (1931), Fisher (1948), and Wilkinson (1951) also
proposed methods for meta-analysis. Today, meta-analysis is widely used in epidemiology
and evidence-based medicine.
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By far the most common use of meta-analysis has been in quantitative literature reviews.
These are review articles where the authors select a research finding that has been investi-
gated in a certain research project under a large number of different circumstances. They
then use meta-analysis to help them describe the overall strength of the effect, and under
what circumstances it is stronger and weaker.
Recently, as knowledge of meta-analytic techniques has become more widespread, re-
searchers have begun to use meta-analyitc summaries within research papers. In this case,
meta-analysis is used to provide information supporting a specific theoretical statement,
usually about the overall strength or consistency of a relationship within the studies being
conducted. As might be expected, calculating a meta-analytic summary is typically a much
simpler procedure than performing a full quantitative literature review.
In general, two metrics are commonly combined in the meta-analysis. The first metric
combines significance levels or their transformation scores. The famous Fisher’s method
belongs to this category that sums up the log-transformed p-values. Many other statistics
including a trimmed version of Fisher’s method (Olkin and Saner, 2001), minimum p-value
(Tippett, 1931) and Wilkinson’s (1951) rth smallest p-value have also been considered. The
second metrix is to combine effect sizes of each study to generate a conclusion of overall effect
size and its confidence interval, which is commonly seen in the research of evidence-based
medicine.
1.2.2 Traditional methods for combining significance levels
[1] Tippet’s method
Tippet et al (1931) proposed a method to deal with meta-analysis. It is a technique to take
the minimum p-value over different studies. The formula is
V minP = min
1≤i≤S
pi (1.1)
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Null hypothesis is rejected if V minP ≤ 1 − (1 − α)1/S. Here α is the overall significance
level and V minP follow a Beta(1, S) distribution under null hypothesis. This method is sensi-
tive to outliers, so a variant uses the rth smallest p-value as an alternative (Wilkinson, 1951).
[2] Fisher’s Method
Fisher et al (1948) proposed a method for meta-analysis. It is a technique for combining
the results from a variety of independent tests bearing upon the same overall hypothesis as
if in a single large test. If there are S independent experimental studies, Fisher’s method
combines the p-values of these studies and transfroms them into one statistic V having an
χ2 distribution using the formula
V = −2
S∑
i=1
log(pi) (1.2)
The degree of freedom of V is 2S.
Fisher’s method was shown in the literature for its good power under a wide range of
alternative conditions and for being the most asymptotically Bahadur optimal (ABO) among
several commonly used combined tests (Little and Folks, 1971,1973).
[3] Wilkinson’s method
Wilkison et al (1951) proposed a method for meta-analysis which generalized Tippett’s pro-
cedure to a more robust rth smallest p-value.
V W = p(r) (1.3)
It is obvious that Maximum p-value is a special case of V W and the most frequently
used. It is often refered to as Wilkinson’s method. The formula is as follows:
V maxP = max
1≤i≤S
pi (1.4)
V maxP follow a Beta(S, 1) distribution under null hypothesis. One of our proposed
methods, ANOVA-maxP, applies this idea for detecting genes with interesting intra-class
patterns across multiple Microarray studies.
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1.2.3 Traditional methods for combing effect size
Effect size (ES) is a name given to a family of indices that measure the magnitude of a
treatment effect. Unlike significance tests, these indices are independent of sample size. ES
measures are the common currency of meta-analysis studies that summarize the findings
from a specific area of research. See, for example, the influential meta-analysis of psycholog-
ical, educational, and behavioral treatments by Lipsey and Wilson (1993).
There is a wide array of formulas used to measure ES. For the occasional reader of meta-
analysis studies, like myself, this diversity can be confusing. One of my objectives in putting
together this set of lecture notes was to organize and summarize the various measures of ES.
In general, ES can be measured in two ways:
a) as the standardized difference between two means,
b) as the correlation between the independent variable classification and the individual scores
on the dependent variable. This correlation is called the ”effect size correlation” (Rosnow
Rosenthal, 1996).
These notes begin with the presentation of the basic ES measures for studies with two
independent groups. The issues involved when assessing ES for two dependent groups are
then described.
For convenience sake we will assume that our contrast will be defined as (treatment group
v.s. control group). When considering the role of this difference in the design of the study
we will call the variable differentiating these groups as the ”treatment factor”.
The simplest effect size based on mean differences is Cohen’s g, defined as
g =
Y¯t − Y¯c
sp
(1.5)
where Y¯t is the mean of the treatment group, Y¯c is the mean of the control group, and
sp is the pooled sample standard deviation.
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While intuitive, the effect size g is actually a biased estimator of the population effect
size
δ =
µt − µc
σ
(1.6)
Using g produces estimates that are too large, especially with small samples.
To correct g we multiply it by a correction term
Jm = 1− 3
4m− 1 (1.7)
where m = nt + nc − 2. The resulting statistic
d = g · (1− 3
4m− 1) = g · (1−
3
4(nt + nc)− 9) (1.8)
is known as Hedges’s d, and is an unbiased estimator of δ. It is generally best to record
both g and d for each effect in our meta-analysis.
The variance of d, given relatively large samples, is
σ2d =
nt + nc
ntnc
+
d2
2(nt + nc)
(1.9)
Using these statistics we can construct a level C confidence intervel for δ
d± z∗(σd) (1.10)
Where z∗ is the critical value from the normal distribution, such that the area between
−z∗ and z∗ is equal to C.
There are many developed formulas to calculate g from a number of different test statis-
tics. One thing worthy to remember is that no matter which formula you choose to use, you
should correct g for its sample size bias using the equation presented above.
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1.2.4 Correlation of effect sizes
Correlations are widely used outside of meta-analysis as a measure of the linear relationship
between town continuous variables. The correlation between two variables x and y may be
calculated as
rxy =
∑
zxizyi
n
(1.11)
where zxi and zyi are the standardized scores of the x and y for case i, n is the sample size.
Correlations can range between -1 and 1. Correlations near -1 indicate a strong negative
relationship; correlations near 1 indicate a strong positive relationship, while correlations
near 0 indicate a nolinear relationship.
The correlation coefficient r is a slightly biased estimator of ρ, the population correla-
tion coefficient. An approximation of the population correlation may be obtained from the
formula
G(r) = r +
r(1− r2)
2(n− 3) (1.12)
The sampling distribution of a correlation coefficient is somewhat skewed, especially if
the population correlaion is large. It is therefore conventional in meta-analysis to convert
correlations to z scores using Fisher’s r-to-z transfromation as
zr =
1
2
ln(
1 + r
1− r ) (1.13)
where ln(x) is the natural logarithm function. All meta-analytic calculations are then
performed using the transformed values. zr has a nearly normal distribution with variance
s2z =
1
n− 3 (1.14)
Using these statistics we can construct a level C confidence interval for the population
value
zr ± z
∗
√
n− 3 (1.15)
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where z∗ is the critical value from the normal distribution such that the area between
−z∗ and z∗ is equal to C.
If we wish to work with unbiased estimates of ρ, you should first calculate the correlation
G(r) for each study and then transform the G(r) values to z-scores for analysis.
Once we have made the necessary computations, we can use Fisher’s z-to-r transforma-
tion
r =
e2zr − 1
e2zr + 1
(1.16)
where e is the base of the natural logarithm, to convert the results back into correlations.
1.3 MICROARRAY META-ANALYSIS
As we mentioned in the previous sections, microarray is a useful technology which provides
an opportunity for global monitoring of the expression levels of thousands of genes simultane-
ously. This technology evolved from Southern blotting, where fragmented DNA is attached
to a substrate and then probed with a known gene or fragment. The use of a collection of
distinct DNAs in arrays for expression profiling was first described in 1987, and the arrayed
DNAs were used to identify genes whose expression is modulated by interferon.
The use of miniaturized microarrays for gene expression profiling was first reported in
1995. As the technology matures and becomes prevalent in biomedical research, many data
sets have been accumulated in the public internet domain, for example, the NCBI Gene
Expression Omnibus (Edgar et al., 2002), the EBI ArrayExpress (Parkinson et al, 2005)
and the Stanford Microarray Database (Sherlock et al, 2001). The development of effective
information integration of multiple microarray studies has gained increasing attention.
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Microarrays present new statistical problems because the data is very high dimensional
with very little replication. Microarrays offer an exciting entry point for statisticians and
computational scientists into the modern areas of computational biology and bioinformatics.
Among various types of microarray statistical analysis, detection of differentially ex-
pressed (DE) genes is one of the most important goals. Samples under two different condi-
tions (e.g. normal versus diseased patients) are examined. Many statistical methods have
been proposed for detecting biomarkers differentially expressed across the two classes (Bre-
itling et al, 2004; Efron et al, 2001; Newton et al, 2004; Tusher et al, 2001).
When multiple microarray studies are available, meta-analysis is expected to increase
statistical power for DE gene detection. Rhode et al (2002) was among the first to apply
traditional Fisher’s method (Fisher, 1948) for combining multiple microarray studies. Many
other approaches have been proposed later, including a lasso-based method (Ghosh et al,
2003), random effects models (Choi et al, 2003; Stevens and Doerge, 2005), Bayesian methods
(Tseng et al, 2001; Jung et al, 2006; Conlon et al, 2007), rank-based approaches (Breitling et
al, 2004; Hong et al, 2006) and others. We will introduce two methods for combining effect
size in microarray meta-analysis below.
1.3.1 Modern methods for combining effect size in microarrary meta-analysis
When studies have a similar design and measure the outcome in a similar manner, combining
estimates is usually preferred by some researchers to the omnibus methods in the previous
section as suggested by some researchers. In this section we will introduce the two most
used methods in this area, either the fixed or the random effects model (Hedges and Vevea,
1998).
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Let T and C stand for two experimental conditions (treatment verses control), and let
there be S independent studies and (niT , niC) replicates for the ith study. Briefly, a standard-
ized mean difference was obtained as an effect size index for the measurement of differential
expression of a gene in any given study.
di =
T¯i − C¯i
Sp
Where T¯i and C¯i represent the means of treatment and control group in the ith study,
and Sp indicates the estimated variation. Then we can model the effect size index di across
studies as follows:
di = θi + εi, εi ∼ N(0, si2)
θi = µ+ δi, δi ∼ N(0, τ 2)
where µ denotes the parameter of interest (treatment effect), and s2i and τ
2 represent
the within-study and between-study variance.
1.3.2 Fixed effects model
Fixed effects models consider only within-study variability, s2i , and assume that all studies
use identical methods, samples and measurements. They also assume there is a constant
effect size µ for all studies. It means that θ1 = θ2 = ... = θS = µ. Thus, di ∼ N(µ, s2i ). The
most efficient and unbiased estimator of µ is
µˆ =
∑S
i=1(s
2
i )
−1di∑S
i=1(s
2
i )
−1
and the variance of µˆ is
V ar(µˆ) =
1∑S
i=1(s
2
i )
−1
A Z-score will be derived from µˆ/
√
V ar(µˆ) to test the null hypothesis when
∑S
i=1(niT + niC)→∞.
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1.3.3 Random effects model
As an alternative approach, the random effects model allows the study outcomes to vary in
a normal distribution among studies. That is, the true study effect size θi is no longer a
constant effect and varies across studies. We represent the equations as follows:
di = θi + εi, εi ∼ N(0, si2)
θi = µ+ δi, δi ∼ N(0, τ 2)
The estimator of µ is
µˆ =
∑S
i=1(s
2
i + τ
2)−1di∑S
i=1(s
2
i + τ
2)−1
and the variance of µˆ is
V ar(µˆ) =
1∑S
i=1(s
2
i + τ
2)−1
A Z-score will be derived from µˆ/
√
V ar(µˆ) to test the null hypothesis.
1.4 TWO COMPLEMENTARY HYPOTHESIS SETTINGS
Li and Tseng (2009) elucidated two statistical hypothesis settings behind two separate bi-
ological goals in combining multiple array studies. We consider meta-analysis of K gene
expression profile studies: D1, D2, ..., Dk, xkgs is the gene expression intensity of gene g and
sample s, where sample s = 1, ..., nk belong to a normal group and s = nk + 1, ..., nk +mk
belong to the disease group. Normally we consider a null hypothesis for each gene g:
H0 : θg1 = · · · = θgK = 0,
where θgk represents the gene effect of gene g and study k. Following the convention of
Birnbaum (1954), two complementary alternative hypotheses can be considered depending
on the nature of the experimental situations in which the gene effects(θgks) are obtained:
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HSA : { H0 versus HA : θgk 6= 0, ∀1 ≤ k ≤ K}
HSB : { H0 versus HB : at least one θgk 6= 0, 1 ≤ k ≤ K}
Under the two major alternative hypotheses categories, different subset or variations have
been explicitly or implicitly targeted by different existing methods:
HSA1 : {H0 versus HA1 : θg = θg1 = ... = θgk 6= 0}
HSA2 : {H0 versus HA2 : θg 6= 0, θgk ∼ N(θg, τ 2)}
HSBh : {H0 versus HBh :
∑K
k=1 I(θgk 6= 0) = h (1 ≤ h ≤ K)}
HSBh′ : {H0 versus HBh′ :
∑K
k=1 I(θgk 6= 0) = h and θgk = θg if θgk 6= 0.(1 ≤ h ≤ K)}
I(·) is an indicator function that equals 1 when statement true and 0 otherwise.
Without danger of confusion, we will use the notation of alternative hypothesis (e.g.
HA) to denote the paremeter space of the corresponding alternative hypothesis. It is clear
that HA ⊂ HB. In HA, gene g is identified only when it is differentially expressed in all
studies. In HB, it is selected if it is differentially expressed in one or more studies. We can
easily note that HA1 ⊂ HA represents an equal fixed effect model. HA2 represents a random
effect model for a similar purpose of HA while HA2 6⊆ HA in general. We also can find that
HB =
⋃
1≤h≤K HBh, HBh′ ⊆ HBh (1 ≤ h ≤ K) and HBK′ = HA1.
An optimally-weighted statistic was modified from the Fisher’s score and was proposed
for the former hypothesis setting (HA1). The optimal weights provided natural categorization
of the detected biomarkers for further biological investigation.
1.5 MOTIVATION
The current methods in Microarray meta-analysis, including those described previously, just
focus on the detection of differentially expressed (DE) genes between two-class ‘disease-
versus-normal’ or ‘treatment-versus-control’ setting. Methods for combining studies with
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more than two classes are rarely discussed. This is the reason why we would like to propose
a new method to deal with the issue of multiple-class studies in this dissertation. When
more than two classes are considered, no single effect size can be computed, and instead,
the inter-class patterns1 become the concern. The former category is, however, extensible to
data sets with more than two classes. The F-statistics (or equivalent ANOVA model) and
its variants can be applied and p-values can be assessed and combined across studies.
In this dissertation, we explore the method of ANOVA-maxP, which detects biomarkers
with a significant pattern (large between-class variance versus small within-class variation)
in all studies. We also note that small p-values (equivalently large F-statistics) in all studies
do not guarantee consistent inter-class patterns across studies. We can use real data as an
illustration. Table 2 shows mouse metabolism data which has four tissues (brown fat, liver,
heart and skeletal) and within each tissue there are three genotypes (Wilde Type, VLCAD,
LCAD)2. The replicates of each tissue within each genotype are slightly different and the
total number of arrays are 44.
Table 2: Mouse metabolism data
tissue type brown fat liver heart skeletal Total
genotype WT V- L- WT V- L- WT V- L- WT V- L-
n of arrays 4 4 4 4 4 4 3 4 4 3 3 3 44
WT: wilde type; V-:VLCAD; L-:LCAD
We can treat each tissue as a study and each genotype as a class, so now we have a
Microarray meta-analysis data set with four studies and within each study has three classes.
Then we applied ANOVA-maxP to do the biomarker detection. Figure 3 shows two genes
in mouse metabolism data detected by ANOVA-maxP and the inter-calss patterns across
1In a loose definition, the ”inter-class pattern” is defined as the vector of mean indensities in the classes
within a study when the within-class variation is very small
2More details are described in section 1 of chapter 3
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studies are concordant (the upper one) and discordant (the lower one). In Figure 3, we can
see that Gene Amacr has a concordant inter-class pattern across these four tissues. It has
high expression levels in two genotypes (WT, LCAD) and a low expression level in VLCAD,
regardless of the kind of tissue. Gene Scd1 is also detected by ANOVA-maxP, however, it
does not have a concordant inter-class pattern across these four tissues.
To overcome this issue, we develop a pairwise multi-class correlation (MCC) measure.
The correlation measure is defined through an equal-weight bivariate mixture model from the
multi-class observations. A min-MCC algorithm is extended for combining multiple studies
and the method guarantees the detection of only concordant inter-class pattern biomarkers.
The methodologies and procedures of these two methods are described in Chapter 3. We also
included the performance of ANOVA-maxP and min-MCC assessed through simulation and
applications to a multi-tissue mouse energy metabolism data set and a multi-platform mouse
trauma data set. The result shows that ANOVA-maxP detects genes with both concordant
and discordant inter-class patterns and min-MCC only detects genes with concordant inter-
class genes. The two methods are complementary and serve different biological purposes.
In addition to the biomarker detection, we also develop a R depository package for con-
taining the experimental information of these cancer microarray studies and some functions
for data quality control, data operation and retrieval. The details are decribe in Chapter 2.
In Chapter 4, we will make some conclusions and talk about the further works.
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Figure 3: Two examples for inter-class patterns.
Two examples for showing gene expression indensities with and without concordant inter-
class patterns across these four tissues. Box-plots of each genotype in each tissue are plotted
and the mean expression levels are connected. Upper: Gene Amacr, involved in metabolic
process, has a concordant inter-class pattern across these four tissues. Lower: Gene Scd1,
involved in fatty acid synthesis pathway, does not have a concordant inter-class pattern
across these four tissues.
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with that package’s software. Others provide a more thorough overview of the package
or might even discuss general issues related to the package. In the future, we are looking
towards providing vignettes that are not specifically tied to a package, but rather are
demonstrating more complex concepts. As with all aspects of the Bioconductor project,
users are encouraged to participate in this effort.
• Statistical and graphical methods. The Bioconductor project aims to provide access
to a wide range of powerful statistical and graphical methods for the analysis of genomic
data. Analysis packages are available for: pre-processing Affymetrix and cDNA array
data, identifying differentially expressed genes, graph theoretical analyses, and plotting
genomic data. In addition, the R package system itself provides implementations for
a broad range of state-of-the-art statistical and graphical techniques, including linear
and non-linear modeling, cluster analysis, prediction, resampling, survival analysis, and
time-series analysis.
• Annotation. The Bioconductor project provides software for associating microarray
and other genomic data in real time to biological metadata from web databases such as
GenBank, LocusLink and PubMed (annotate package). Functions are also provided for
incorporating the results of statistical analysis in HTML reports with links to annota-
tion WWW resources. Software tools are available for assembling and processing genomic
annotation data, from databases such as GenBank, the Gene Ontology Consortium, Lo-
cusLink, UniGene, the UCSC Human Genome Project (AnnotationDbi package). Data
packages are distributed to provide mappings between different probe identifiers (e.g.
Affy IDs, LocusLink, PubMed). Customized annotation libraries can also be assembled.
• Bioconductor short courses. The Bioconductor project has developed a program
of short courses on software and statistical methods for the analysis of genomic data.
Courses have been given for audiences with backgrounds in either biology or statistics.
All course materials (lectures and computer labs) are available on the WWW. Customized
short courses may also be designed for interested parties.
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• Open source. The Bioconductor project has a commitment to full open source disci-
pline, with distribution via a SourceForge-like platform. All contributions are expected
to exist under an open source license such as Artistic 2.0, GPL2, or BSD. There are many
different reasons why open–source software is beneficial to the analysis of microarray data
and to computational biology in general. The reasons include:
– To provide full access to algorithms and their implementation
– To facilitate software improvements through bug fixing and software extension
– To encourage good scientific computing and statistical practice by providing appro-
priate tools and instruction
– To provide a workbench of tools that allow researchers to explore and expand the
methods used to analyze biological data
– To ensure that the international scientific community is the owner of the software
tools needed to carry out research
– To lead and encourage commercial support and development of those tools that are
successful
– To promote reproducible research by providing open and accessible tools with which
to carry out that research (reproducible research is distinct from independent veri-
fication)
2.2.4 A simple example: AnnotationDbi
AnnotationDbi is used primarily to create maps that allow easy access from R to underlying
annotation databases. AnnotationDbi introduces a new future for the Bioconductor anno-
tation data packages by changing the paradigm that is used for exchanging annotations.
We will use a database called hgu95av2.db to be an illustration. This database is for a
Affymetrix array whose name is HgU95AV2.
First of all, we need to call this database into R
R> library("hgu95av2.db")
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The same basic set of objects is provided with this databse package:
R> ls("package:hgu95av2.db")
[1] ”hgu95av2” ”hgu95av2 dbconn”
[3] ”hgu95av2 dbfile” ”hgu95av2 dbInfo”
[5] ”hgu95av2 dbschema” ”hgu95av2ACCNUM”
[7] ”hgu95av2ALIAS2PROBE” ”hgu95av2CHR”
[9] ”hgu95av2CHRLENGTHS” ”hgu95av2CHRLOC”
[11] ”hgu95av2CHRLOCEND” ”hgu95av2ENSEMBL”
[13] ”hgu95av2ENSEMBL2PROBE” ”hgu95av2ENTREZID”
[15] ”hgu95av2ENZYME” ”hgu95av2ENZYME2PROBE”
[17] ”hgu95av2GENENAME” ”hgu95av2GO”
[19] ”hgu95av2GO2ALLPROBES” ”hgu95av2GO2PROBE”
[21] ”hgu95av2MAP” ”hgu95av2MAPCOUNTS”
[23] ”hgu95av2OMIM” ”hgu95av2ORGANISM”
[25] ”hgu95av2PATH” ”hgu95av2PATH2PROBE”
[27] ”hgu95av2PFAM” ”hgu95av2PMID”
[29] ”hgu95av2PMID2PROBE” ”hgu95av2PROSITE”
[31] ”hgu95av2REFSEQ” ”hgu95av2SYMBOL”
[33] ”hgu95av2UNIGENE” ”hgu95av2UNIPROT”
To demonstrate the steps for converting probe set IDs of HgU95AV2 to EntrezID, we’ll start
with a random sample of probe set IDs.
R> all probes < − ls(hgu95av2ENTREZID)
R> length(all probes)
[1] 12625
There are 12625 probe set IDs in HgU95AV2.
R> set.seed(0xa1beef)
R> probes < − sample(all probes, 5)
R> probes
[1] ”31882 at” ”38780 at” ”37033 s at” ”1702 at” ”31610 at”
These are the probe set IDs which are randomly selected from HgU95AV2. The usual
ways of accessing annotation data are by using the package: hgu95av2ENTREZID. Suppose
we would like to know the EntrezID of ”31882 at”, there two ways to do it: using the order
number of ”31882 at” in the set of probes or the probe set ID directly. Below are the
demostrations.
R> hgu95av2ENTREZID[[probes[1]]]
[1] ”9136”
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R> hgu95av2ENTREZID$"31882 at"
[1] ”9136”
The EntrezID of ”31882 at” is 9136.
If we would like to know the symbols (gene names) of probes, we can use the function: mget.
R> syms < − unlist(mget(probes, hgu95av2SYMBOL))
R> syms
31882 at 38780 at 37033 s at 1702 at 31610 at
”RRP9” ”AKR1A1” ”GPX1” ”IL2RA” ”PDZK1IP1”
The symbols of these five probe set IDs are annotated successfully. For more details about
Bioconductor, please refer to www.bioconductor.org.
2.3 R PACKAGES FOR CANCER STUDY DEPOSITORY
Before we do any kind of microarray meta-analysis, the first step is collecting enough data
sets and containing the information of the experiment as much as possible. Thus, creating
a convenient and useful structure of depository for the data sets is a very important work.
For fulfilling this purpose, we developed a data depository based on the idea of eSet in
Bioconductor and can be executed in R. This kind of structure has the following features:
• Simplified data content.
• Structured class hierarchy.
• Alternative storage modes.
• More validity checking.
This depository package is constituted of four components, assayData, phenoData,
featureData, experimentData. The details of these four components are as follows:
• assayData:
This is a matrix containing the gene expression values of the cancer study. Rows are
features, e.g., gene IDs. And columns are samples represented on each study.
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• phenoData:
(1)pData: Rows are sample identifiers and columns are measured covariates, like age,
sex, tumor type, survival status, or other experimental information of samples.
(2)pheno varDescrptn: Rows are measured covariate labels and columns are covariate
descriptors.
• featureData:
(1)fData: Rows are feature identifiers. These match row names of assayData. Columns
are measured covariates.
(2)feature varDescrptn: Rows are measured covariate labels. Columns are covariate
descriptors.
• experimentData:
This is an information structure based on MIAME (Minimum Information About a
Microarray Experiment) protocol, and includes
– name: the last name of the first author on the paper
– lab: the last name of the last author on the paper
– contact: the contact information of responding author
– title: the title of the paper
– abstract: the abstract of the paper
– url: the link of the paper
– pubMedIds: the pubMed ID
– citation: the citation of this paper
– organism: the organism which the paper used
– data url: the data link of this study
– GEO: GEO number of this data set
– journal: the journal in which this paper was published
– year: the year in which this paper was published
– geneIDType: what kind of gene ID in this data set
– annotation: what kind of array type did this study use
We are going to illustrate the functions of this package by the Magee study, a prostate cancer
study published in ”Cancer Research”, 2001. Its array type is Affymetrix HG6800. We have
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already prepared the four components and saved them in a depository package which is
named ”Magee”. So, if we type Magee in R, like
R> Magee
You will see the following information:
ExpressionSet (storageMode: lockedEnvironment)
assayData: 7129 features, 15 samples
element names: exprs
phenoData
sampleNames: Benign.1, Benign.2, ..., Met3 (15 total)
varLabels and varMetadata description:
Cell type: Benign: Benign, Primary: Tumor, Met: Metastasis
Tumor type: Normal: Benign, Tumor:Primary, Other: Metastasis
featureData
featureNames: AFFX-BioB-5 at, AFFX-BioB-M at, ..., Z78285 f at (7129 total)
fvarLabels and fvarMetadata description:
geneID: AFFY.HU6800
experimentData: use ’experimentData(object)’
pubMedIds: 11479199
Annotation: HG6800
From the messages above, we can see that there are 15 samples in this study and that
within each sample there are 7129 probe set IDs. The array type for this study is HG6800. If
you would like to know more details about this experiment, type in experimentData(Magee),
then you will get all the experimental information.
We have collected about 66 cancer studies in our database and the total number is
growing continually. Table 3 shows a brief summary of the cancer types and array types in
the database.
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Table 3: Summary of the studies in the database
Cancer Type
Cancer type Breast Colon Leukemia Lung Prostate Total
Number of studies 16 11 13 10 16 66
Array Type
Array type cDNA Affymetrix Aligent Total
Number of studies 15 50 1 66
More details of these studies about the lab, year, and array types, are in Appendix A.
2.4 FUNCTIONS TO OPERATE THE PACKAGES
2.4.1 Function for data quality evaluation
For microarray meta-analysis, data collection is the first step. Once we get enough numbers
of data sets, the next step is evaluating the quality of these data sets, because if we include
the samples with bad quality in our down-stream analysis, it could give us wrong information
and cause bias of the biomarker detection. For this purpose, we developed a package which
is named dataQE to do some qualtiy checking of microarray studies before doing the data
analysis.
2.4.1.1 Principles and steps The principles of dataQE is based on Pearson correlation
and the idea of mean and standard deviation. There are two parts in this package. The
first one is for evaluating sample quality and the second one is for evaluating the sample
normalization. The steps are as follows:
Sample Quality Evaluation
Suppose we have a study S and there are K samples in this study.
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[1] Firstly, dataQE calculates pair-wise correlations of these K samples. We will get a sym-
metric matrix, C , containing these pair-wise correlations.
[2] Secondly, taking the mean of each row of C, we will get a set of numbers, M, with K
values of mean of the pair-wise correlations.
[3] Thirdly, calculating the mean and standard deviation of M separately, denoted by corMean
and corSD. If Mi ≤ corMEAN− 3 ∗ corSD, then sample i will be considered as a sample with
bad quality, because the average correlation with other samples is much lower than others.
Sample Normalization Evaluation
The second part of dataQE is for evaluating the sample normalization. The steps are as
follows:
[1] Firstly, dataQE calculates the mean of sample i , denoted by meani, where (1 ≤ i ≤ K).
[2] Secondly, taking the mean and standard deviation of these meanis , denoted by Sample mean
and Sample meanSD. If |meani| ≥ Sample mean+ 3 ∗ Sample meanSD, then sample i will be
considered as a sample with bad normalization in mean values, because the mean is much
lower than others.
Similarly, dataQE will calculate the standard deviation of each sample, denoted by sdi,
and calculate the mean and standard deviation of sdis, denoted by Sample SDmean and
Sample sdSD separately.
If |sdi| ≥ Sample SDmean+ 3 ∗ Samle SDsd, then sample i will be considered as a sample
with bad normalization via standard deviation, because the standard devation is much lower
than others.
2.4.1.2 An example of real data Now we will use real data to demonstrate how dataQE
works. It is prostate caner data with 148 samples, and tje data name in R is pnew. If we
type dataQE(pnew) in R, it will show the following warning messages,
Warning:These samples may not have good quality: 7 87 88 89
Warning:These samplee may not have good normalization: 7 87 88 94 95
36
It means that sample 7, 87, 88, 89 have lower average correlation than other samples, and
sample 7, 87, 88, 94, 95 have worse normalization than others. Users can refer to these
warning messages and consider if it is necessary to remove these samples before doing any
microarray data analysis. Figure 4 shows the heatmaps without and with removing these
samples. It looks like we can get better and robust data after removing these samples.
There is another option in dataQE: plot=TRUE. If you type dataQE(data,plot=TRUE),
it will give you four plots: (1) histogram of sample correlations, (2) histogram of
sample means, (3) histogram of sample standard deviations, (4) a list of questionable
samples. For example, if we type dataQE(pnew,plot=TRUE) in R, then we will get a figure
with four plots as shown in Figure 5.
2.4.2 Functions for data operation and retrieval
What we have discussed above just focused on a single study. We collected data sets one by
one and saved them in a depository package in R. Now we can do some quality evaluation
before doing the down-stream analysis. However, our purpose is not only talking about the
matters in a single microarray study. What we would like to do is microarray meta-analysis.
So, it is necessary for us to merge these data sets before doing analysis. Therefore, we
developed two functions for this purpose.
2.4.2.1 Function for gene ID convertion As we mentioned in 1.1.3, there are many
different microarray types and all of their gene identifiers (gene IDs) are also different. When
we want to merge these different studies, we will encounter the problem of gene ID matching
among these studies. For solving this problem, we developed a function which is named
gene.match. In gene.match, we choose EntrezID as our medium to merge data sets. It
means any kind of gene IDs of microarray platforms will be converted to EntrezID first and
then thees EntrezIDs will be used to merge studies.
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A C
B D
Figure 4: Heatmaps of dataQE results.
Heatmaps without and with removing the questionable samples which were detected by
dataQE. A: All samples are included. B: Remove 3 lowest correlation samples (7,87,88). C:
Remove 4 lowest correlation samples (7,87,88,89). D: Remove 4 lowest correlation samples
(7,87,88,89),and 2 lowest column mean samples (94,95).
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Figure 5: dataQE outputs if plot=TRUE.
dataQE outputs if plot=TRUE. Upper left: Histogram of average pair-wise correlations.
Lower left: Histogram of Sample standard deviations. Upper right: Histogram of sample
means. Lower right: Questionable samples.
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There is another problem when we do gene-matching by EntrezID. It could happen
that some gene IDs may convert to the same EntrezID, therefore we will have duplicated
EntrezIDs after conversion. There are two options in gene.match to solve this problem. One
is "average" and another one is "IQR"1.
For Affymetrix array, we have prepared the functions for HU6800, HGU133, HGU133A,
HGU133A2, HGU133B, HGU133PLUS2, HGU95A, HGU95Av2. For cDNA array, we have UniGene
ID, GenBank Accession Number, RefSeq Identifiers, Official Gene Symbol, Gene Symbol.
2.4.2.2 Function for correlation of correlations In addition to retrieving the single
gene information among multiple studies, someone could be interested in the genomic cor-
relations of these cancer studies. For this purpose, we developed another function, CorCor,
to calculate the genomic meta-correlations. We call it ”Correlations of Correlations”. The
steps issue are as follows. Suppose we have S studies.
[1] Calculate the pair-wise correlations of whole genes in each study.
[2] Applying the concepts in 1.2.4 to do a modification and transformation to get unbiased
estimators and r − to− z score for meta-analysis correlations.
[3] Calculate the pair-wise correlations between any two of the S studies and show the results
as a symmetric correlation matrix.
For example, if we type the following code in R,
da <- list(brown,liver,heart,ske)
na <- c("brown","liver","heart","ske")
CorCor(da,names=na)
CorCor will give you the following correlation matrix,
1IQR is the abbreviation of Interquartile range. More details are described in Appendix B
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brown liver heart ske
brown 1.00000000 0.0948003492 0.0976056777 0.0006159800
liver 0.09480035 1.0000000000 0.0510178781 0.0008724284
heart 0.09760568 0.0510178781 1.0000000000 0.0007053562
ske 0.00061598 0.0008724284 0.0007053562 1.0000000000
2.4.2.3 Function for gene retrieving of clinical features Before any biomarker de-
tection, based on some knowledge, the biologists could be roughly interested in the expression
behavior of a certain gene among different data sets or cancer studies. For this purpose, we
developed a function, meta.gene.retrieve. There are five parts in this function.
1. data: a list of data sets which the user would like to investigate.
2. gene: the name of the gene that the user is interested in. It should be included in double
quotes, ””.
3. ID.Type: the ID type of gene. For Affymetrix array, the options are HU6800, HGU133,
HGU133A, HGU133A2, HGU133B, HGU133PLUS2, HGU95A, HGU95Av2. For cDNA array,
the options are UniGene ID, GenBank Accession Number, RefSeq Identifiers, Official
Gene Symbol, Gene Symbol.
4. plot.type: plot types of the results. There are two types, ”boxplot” and ”CI” (95%con-
fidence interval), which users can choose.
5. study.names: a list of the names of data sets in data.
6. pool.replicate: the pool methods for duplicated genes in gene convertion. There are
two options, ”average” and ”IQR”, which users can choose.
For example, MT1H is an important gene in metabolism processes and we would like
to know the expression behavior among some interesting cancer data sets, prostate cancer:
Magee, Welsh, Luo, Dhanasekaran, Singh, Varambally, and lung cancer: Bhattacharjee,
Garber, Beer, Wachi, Gordon. This function is only for the comparison of ” Normal vs.
Tumor”. If we would like to use box-plot as the plot type and ”IQR” as the pool.replicated
method, the following commands are used,
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data <- list(Magee,Welsh,Luo,Singh,Varambally,Bhattacharjee,Beer,Wachi,Gordon)
sname <- c("Magee","Welsh","Luo","Singh","Varambally","Bhattacharjee","Beer",
"Wachi","Gordon")
meta.gene.retrieve(data=data, gene="MT1H", ID.Type="SYMBOL", plot.type=c("boxplot"),
study.names=sname, pool.replicate="IQR")
We will get the results as shown in Figure 6. On the bottom of each box-plot, meta.gene.retrieve
will show the sample size and provide the p-value of a simple t-test.
If there is not such a comparison type in this dataset, meta.gene.retrieve will show "NO
SUCH TYPE" in the middle of the plot. If there is not a gene in this dataset, meta.gene.retrieve
will show "NO SUCH GENE".
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Figure 6: MT1H Retrieve Plots.
Box plots of the expression levels of MT1H among different cancer data sets. On the bottom
of each plot, meta.gene.retrieve provides the p-values of simple t-test
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3.0 BIOMAKER DETECTION METHODS FOR MULTIPLE
MULTI-CLASS STUDIES
As the microarray technology becomes mature and prevalent in biomedical research, an
increasing number of data sets have been accumulated in the public domain. Systematic
information integration of multiple related studies should improve biomarker detection. So
far, published meta-analysis methods for this purpose mostly consider two-class compari-
son. Methods for combining multi-class studies and pattern concordance have been rarely
explored.
We first consider a natural extension of combining p-values from the traditional ANOVA
model. Since p-values from ANOVA do not guarantee to reflect the concordant expression
pattern information across studies, we propose a multi-class correlation measure (MCC) to
specifically look for biomarkers of concordant inter-class patterns across a pair of studies. For
both approaches, we focus on identifying biomarkers differentially expressed in all studies
(i.e. ANOVA-maxP and min-MCC). The min-MCC method is further extended to identify
biomarkers differentially expressed in partial studies using an optimally-weighted technique
(OW-min-MCC). All methods are evaluated by simulation studies and by three meta-analysis
applications to multi-tissue mouse metabolism data sets, multi-condition mouse trauma data
sets and multi-malignant-condition human prostate cancer data sets.
In general, we consider S studies to be combined (S = 4 in mouse metabolism data and
S = 2 in mouse trauma data). Among each study, K classes of samples are measured with
nsk replicates for study s and class k. Denote by xsgki the expression intensity of gene g (1
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≤ g ≤ G), study s (1 ≤ s ≤ S), class k (1 ≤ k ≤ K) and replicated sample i (1 ≤ i ≤ nsk).
In this proposal, we particularly consider the situation when K > 2.
3.1 ANOVA-MAXP FOR MULTIPLE STUDIES
ANOVA-maxP is a natural extension of the traditional p-value based meta-analysis method.
The method is to take, for each gene, the maximum p- value observed over the S studies
as the test statistic. As a result, a biomarker is conservatively detected only if the p-values
for all studies are small. In the multi-class data structure considered, ANOVA model is first
used to test the significance of variation in gene expressions across phenotype classes in each
study. Corresponding p-values from F-test are then combined by taking the maximum.
3.1.1 Procedure for ANOVA-maxP
1. Compute F-statistics, Fgs, for gene g in the sth study.
2. Permute group labels in each study for B times, and similarly calculate the permuted
statistics,F
(b)
gs where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.
3. Estimate p-value of Fgs as
pgs =
∑B
b=1
∑G
g′=1 I(F
(b)
gs ≥ Fgs)
(B ·G) (3.1)
where I(·) is the indicator function that takes values one when the statement is true and
zero otherwise.
Similarly given F
(b)
gs , compute p-value of F
(b)
gs as
pbgs =
∑B
b′=1
∑G
g′=1 I(F
(b′)
gs ≥ Fgs)
(B ·G) (3.2)
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4. The maximum P-value statistic is defined as
Vg = max
1≤s≤S
pgs
. Similarly define
V (b)g = max
1≤s≤S
p(b)gs
.
5. Estimate p-value of Vg by
p(Vg) =
∑B
b=1
∑G
g′=1 I(V
(b)
g′ ≤ Vg)
(B ·G) (3.3)
6. Estimate q-value for each gene as
q(Vg) = pi0
∑B
b=1
∑G
g′=1 I(V
(b)
g′ ≤ Vg)
(B
∑G
g′=1 I(V
′
g ≤ Vg))
(3.4)
where pi0 is the estimate of proportion of null genes. A conservative suggestion is to set
pi0 as 1. Genes with q-values smaller than 0.05 are detected as biomarkers.
3.2 MULTI-CLASS CORRELATION(MCC) FOR A PAIR OF STUDEIS
Below we describe our proposed pairwise multi-class correlation measure (MCC), given a
gene, in two studies. For simplicity, we drop the subscript of gene g and studies s. Con-
sider xkj(1 ≤ k ≤ K, 1 ≤ j ≤ nk) to represent expression intensity of class k, sample j
for the first study and ykj(1 ≤ k ≤ K, 1 ≤ j ≤ mk) for the second study. A naive mea-
sure to quantify the correlation of the expression patterns across two studies may be the
direct sample correlation of (x11, ..., x1n1 , ..., xk1, ..., xknk) and (y11, ..., y1m1 , ..., yk1, ..., ykmk)
if nk = mk,∀k. However, since nk 6= mk in general and this naive definition ignores the
exchangeability within (x11, ..., x1nk) and (y11, ..., y1nk) for a given 1 ≤ k ≤ K, we need to
develop a better-defined correlation measure.
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Assume we know the underlying distribution Xk and Yk, where xkj are i.i.d. from Xk,
ykj are i.i.d. from Yk. E(Xk) = µXk , E(Yk) = µYk , V ar(Xk) = σ
2
Xk
, V ar(Yk) = σ
2
Yk
. Aslo
assume Xk’s and Yk’s are independent. Define a bivariate distribution(X,Y) to be the equal
mixture of bivariate distributions(Xk, Yk), such that
F(X,Y )(s, t) =
1
K
K∑
k=1
F(Xk,Yk)(s, t) =
1
K
K∑
k=1
F(Xk)(s)F(Yk)(t) (3.5)
where FX(·) represents the cumulative distribution function of X. We define the multi-
class correlation (MCC) measure of (X1, ..., Xk) and (Y1, ..., YK) to be cor(X,Y ) as the
Pearson correlation of X and Y . It can be easily shown that
MCC = cor((X1, ..., XK), (Y1, ..., YK)) =
E(XY )− EX · EY√
V ar(X) · V ar(Y ) (3.6)
( 1
K
∑K
k=1 µXkµYk)− ( 1K
∑K
k=1 µXk)(
1
K
∑K
k=1 µYk)√
[ 1
K
∑K
k=1 σ
2
Xk
+ 1
K
∑K
k=1(µXk − µX)2][ 1K
∑K
k=1 σ
2
Yk
+ 1
K
∑K
k=1(µYk − µY )2]
(3.7)
where
µX =
1
K
K∑
k=1
µXk (3.8)
and
µY =
1
K
K∑
k=1
µYk (3.9)
This correlation measure takes values between -1 and 1. A large positive correlation
indicates similar patterns between two studies for a given gene.
When n1 = n2 = ... = nK = n and m1 = m2 = ... = mK = m, MCC can be rewritten as
below:
MCC =
rX¯Y¯√
1
FX
+ 1
√
1
FY
+ 1
(3.10)
Where
rX¯Y¯ =
( 1
K
∑
µXkµXk)− ( 1K
∑
µXk)(
1
K
∑
µYk)√
1
K
∑
(µXk − µX)2
√
1
K
∑
(µYk − µY )2
(3.11)
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and
FX =
∑
(µXk − µX)2/K∑ ∑
(xkj − µXk)2/(n ·K)
,
FY =
∑
(µYk − µY )2/K∑∑
(ykj − µYk)2/(m ·K)
(3.12)
From the equation (3.3), FX and FY are related to F-statistic in ANOVA. rX¯Y¯ is the sample
correlation of (µX1 , ..., µXK ) and (µY1 , ..., µYK ). When the within-class variation is much
smaller than the between-class variation, FX and FY become large. MCC converges to rX¯Y¯
as expected.
In practice, distributions of (Xk, Yk) are unknown. The means (µXk and µYk) and the vari-
ances (σXk and σYk) are not available. Instead we are given a set of observations (x˜, y˜),where
x˜ = xkj, 1 ≤ k ≤ K, 1 ≤ j ≤ nk, y˜ = ykj, 1 ≤ k ≤ K, 1 ≤ j ≤ mk. Denote by X ′k the em-
pirical distribution of xkj, 1 ≤ j ≤ nk such that FX′
k
(t) =
∑nk
j=1 I(xkj ≤ t) and similarly
FY ′
k
(t) =
∑nk
j=1 I(ykj ≤ t). Define (X ′, Y ′) to be equal mixture of bivariate distribution
(X ′k, Y
′
k) such that
F(X′,Y ′)(s, t) =
1
K
K∑
k=1
F(X′
k
,Y ′
k
)(s, t) =
1
K
K∑
k=1
F(X′
k
)(s)F(Y ′
k
)(t) (3.13)
The multi-class correlation(MCC) based on observed (x˜, y˜) becomes
MCC = cor(x˜, y˜)) =
E(X ′Y ′)− EX ′ · EY ′√
V ar(X ′) · V ar(Y ′) (3.14)
=
( 1
K
∑K
k=1 µX′kµY ′k)− ( 1K
∑K
k=1 µX′k)(
1
K
∑K
k=1 µY ′k)√
[ 1
K
∑K
k=1 σ
2
X′
k
+ 1
K
∑K
k=1(µX′k − µX′)2][ 1K
∑K
k=1 σ
2
Y ′
k
+ 1
K
∑K
k=1(µY ′k − µY ′)2]
(3.15)
where
µX′ =
1
K
K∑
k=1
µX′
k
, µY ′ =
1
K
K∑
k=1
µY ′
k
(3.16)
,
µX′
k
=
∑nk
j=1 xkj
nk
, µY ′
k
=
∑mk
j=1 ykj
mk
(3.17)
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and
σ2X′
k
=
∑nk
j=1(xkj − µX′k)2
nk
, σ2Y ′
k
=
∑mk
j=1(ykj − µY ′k)2
mk
(3.18)
When n1 = n2 = ... = nK = n and m1 = m2 = ... = mK = m, MCC will have another
form as below which is related to F statistic from ANOVA.
MCC =
rX¯′Y¯ ′√
1
FX′
· K−1
K
+ 1
√
1
FY ′
· K−1
K
+ 1
(3.19)
where
rX¯′Y¯ ′ =
∑
(x¯k − x¯..)(y¯k − y¯..)√∑
(x¯k − x¯..)2
√∑
(y¯k − y¯..)2
(3.20)
and
FX′ =
∑
(x¯k − x¯..)2/(K − 1)∑ ∑
(xki − x¯k)2/(n− 1)K (3.21)
,
FY ′ =
∑
(y¯k − y¯..)2/(K − 1)∑ ∑
(yki − y¯k)2/(n− 1)K (3.22)
From the equation (3.6), FX′ and FY ′ are exactly the F-statistics in ANOVA for x˜ and Y˜ .
rX¯Y¯ is the sample correlation of (µX′
1
, ..., µX′
K
) and (µY ′
1
, ..., µY ′
K
). When the within-class
variation is much smaller than the between-class variation, FX′ and FY ′ become large. MCC
converges to rX¯′Y¯ ′ as expected.
3.2.1 Procedure of MCC for combining two studies
1. Compute MCC statistic, MCCg, for each gene g.
2. Permute group labels in each study for B times, and similarly calculated the permuted
statistics, MCC
(b)
g where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.
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3. Estimate p-value of MCCg as
p(MCCg) =
∑B
b=1
∑G
g′=1 I(MCC
(b)
g′ ≥MCCg)
(B ·G) (3.23)
where I(·) is the indicator function that takes values one when the statement is true and
zero otherwise.
4. Estimate q-value for each gene of MCCg as
q(MCCg) = pi0
∑B
b=1
∑G
g′=1 I(MCC
(b)
g′ ≥MCCg)
(B
∑G
g′=1 I(MCC
′
g ≥MCCg))
(3.24)
where pi0 is the estimate of proportion of null genes. A conservative suggestion is to set
pi0 as 1. Genes with q-values smaller than 0.05 are detected as biomarkers.
3.2.2 Minimum MCC (min-MCC) for more than two studies
The MCC measure described above measures the correlation between two given studies. It
can be extended for identifying genes with a consistent pattern across more than two studies.
The minimum MCC is defined as
min−MCCg = min
1≤u≤v≤S
MCCg(u)(v)
,where MCCg(u)(v) is the MCC measure for gene g and between study u and study v. The
procedures are described as follows:
1. Compute MCC statistic, MCCg(u)(v), for each gene g and for a pair of studies u and v.
2. Permute group labels in each study for B times, and similarly calculate the permuted
statistics, MCC
(b)
g(u)(v) where 1 ≤ g ≤ G, 1 ≤ s ≤ S and 1 ≤ b ≤ B.
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3. Calculate
min−MCCg = min
1≤u≤v≤S
MCCg(u)(v) (3.25)
and
min−MCC(b)g = min
1≤u≤v≤S
MCC
(b)
g(u)(v) (3.26)
4. Estimate p-value of min−MCCg as
p(min−MCCg) =
∑B
b=1
∑G
g′=1 I(min−MCC(b)g′ ≥ min−MCCg)
(B ·G) (3.27)
where I(·) is the indicator function that takes values one when the statement is true and
zero otherwise.
5. Estimate q-value for each gene of min−MCCg as
q(min−MCCg) = pi0
∑B
b=1
∑G
g′=1 I(min−MCC(b)g′ ≥ min−MCCg)
(B · sumGg′=1I(min−MCCg′ ≥ min−MCCg))
(3.28)
where pi0 is the estimate of proportion of null genes. A conservative suggestion is to set
pi0 as 1. Genes with q-values smaller than 0.05 are detected as biomarkers.
3.3 OPTIMALLY-WEIGHTED STATISTICS FOR MINIMUM MCC
(MIN-MCC)
Li and Tseng (2009) proposed an optimally weighted (OW) statistic was modified from the
Fisher’s score and was proposed for the former hypothesis setting HSB. The optimal weights
provided natural categorization of the detected biomarkers for further biological investiga-
tion. They compared this method to the classical Fisher’s equally weighted statistic (EW),
Tippett’s minimum p-value statistic (minP) and Pearson’s statistic (PR).
In general, there exists no uniformly most powerful test. All of the four methods com-
pared are admissible under a simplified Gaussian scenario. Nevertheless, the proposed OW
statistic consistently has the best or near ot the best power in a wide variety of alternative
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hypotheses, especially when EW and minP perform poorly in two extreme alternative hy-
potheses respectively.
3.3.1 An introduction to Optimally-Weighted statistic
When integrating multiple genomic studies, expression of some important biomarkers may
be altered in a study-specific manner (consider HB). To uncover the pattern of altered gene
expression across studies, we consider the following weighted statistic:
Ug(wg) = −
S∑
s=1
wgslog(pgs) (3.29)
where pgs is the p-value of gene g in study s, ws is the weight assigned to the sth study
and wg = (wg1, . . . , wgs). Under the null hypothesis that θgs = 0 ∀ s, the p-value of the
observed weighted statistic, p(ug(wg)), can be obtained for a given gene g and weight wg (see
below for detailed permutation algorithm to calculate the p-value). The optimally-weighted
statistic is defined as the minimal p-value among all possible weights:
V OWg = min
wg∈W
p(ug(wg)) (3.30)
where ug(w) is the observed statistic for Ug(w) and W is a pre-specified searching space. The
choice of searching space in this paper is W = {w|wi ∈ {0, 1}}, which results in an affordabl
computation of O(2K − 1) based on the norm of K ≤ 10 in a microarray meta-analysis. The
resulting optimal weight reflects a natural biological interpretation of whether or not a study
contributes to the statistical significance of a gene.
We note that the OW statistic is not adequate for the traditional meta-analysis in epi-
demiological or evidence-based medicine research. The selection procedure in OW will intro-
duce selection bias towards studies with concordant significant effects. The meta-analysis of
genomic studies, however, is quite a different situation. The major goal is usually to screen
and identify the most probable gene markers given data to facilitate future investigation.
52
The vector of optimal-weight, w∗g = argminwg∈W p(ug(wg)) actually serves as a convenient
basis fogene categorization in the follow-up of biological interpretation and exploration. The
optimal weights obtained from OW have the additional advantages of filtering discordant
biomarkers and providing natural categorization of the detected genes for further biological
investigation.
3.3.2 Procedure for OW-min-MCC
We also applied OW concept in min-MCC for multiple multi-class studies to detected
biomarkers with conditional inter-class patterns across these studies. An algorithm applying
the idea of OW statistics was developed as follows:
Suppose there are S studies, W = {w = (w1, . . . , ws|wi ∈ {0, 1}, 2 ≤
∑S
i=1wi ≤ S})
1. Given a weight w = (wi, . . . , ws), then min-MCC based on w is defined as
Mg(w) = minwu=1,wv=1,1≤u 6=v≤S(MCCg(u)(v)) (3.31)
for study u and v , 1 ≤ g ≤ G.
2. Randomly permute class labels in each study for B times, and similarly calculate the
permuted min-MCC which is defined as
M (b)g (w) = minwu=1,wv=1,1≤u 6=v≤S(MCC
(b)
g(u)(v)) (3.32)
1 ≤ g ≤ G, 1 ≤ b ≤ B.
3. Estimate the p-value of Mg(w) and M
(b)g(w) as
p(Mg(w)) =
∑B
b=1
∑G
g=1 I(M
(b)
g ≥Mg(w))
B ·G (3.33)
p(M (b)g (w)) =
∑B
b′=1
∑G
g′=1 I(M
(b′)
g′ ≥M (b)g (w))
B ·G (3.34)
4. Define Hg as the optimally weighted(OW) statistic of p(Mg(w)), such that
Hg = minw∈Wp(Mg(w))
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Similarly,
H(b)g = minw∈Wp(M
(b)
g (w))
5. Assess p-value of Hg as
p(Hg) =
∑B
b=1
∑G
g′=1 I(H
(b)
g′ ≤ Hg)
B ·G (3.35)
6. Assess q-value of Hg as
q(Hg) =
∑B
b=1
∑G
g′=1 I(H
(b)
g′ ≤ Hg)
B ·∑Gg′=1 I(Hg′ ≤ Hg)
(3.36)
7. Calculate optimal weight as
w∗g = argminw∈Wp(Mg(w)) (3.37)
3.4 RESULTS
3.4.1 Simulation study
We conducted a simulation scenario for combining three genomic studies to assess the per-
formance of our proposed ANOVA-maxP, min-MCC method, and OW-min-MCC. Denote
by xsgki the expression intensity of study s (1 ≤ s), gene g (1 ≤ g ≤ G), sample class k
(1 ≤ k ≤ K) and replicated sample i (1 ≤ i ≤ nsk). In the simulation scenario, we simulated
three studies (S = 3). Each study had three classes (K = 3). The numbers of replicates,
nsk(1 ≤ s ≤ S, 1 ≤ k ≤ K), were different among each class of each study.
A total of G = 2000 genes in each study were simulated. Among these 2000 genes, 300
genes showed concordant inter-class patterns across all studies (category I), 100 genes were
with discordant inter-class pattern (category II), and 100 genes with concordant pattern in
study 1 and study 2 but no pattern in study 3 (category III). The expression intensities were
simulated from xsgki ∼ N(µsk, σ2s). For genes with concordant inter-class pattern, study
1: µ1 = (1, 3, 5), study 2: µ2 = (2, 4, 6), and study 3: µ3 = (1, 4, 7). So, mean vectors
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µs = (µs1, ..., µsk) across studies had pair-wise correlation one. For genes with discordant
inter-class patterns, that study 1 is µ1 = (1, 3, 5), study 2 is µ2 = (6, 4, 2), and study 3:
µ3 = (1, 7, 4) , pair-wise correlations of mean vectors were low or negative. For the genes in
category III, mean vector for study 1 is (1, 3, 5), for study 2 is (2, 4, 6), and (0, 0, 0) for study
3. For the rest of the 1500 genes are null genes form (µs1, ..., µsk) = (0, ..., 0).
The effect size was defined as the ratio of the standard deviation of the mean vectors
to the within class standard deviation, σs. We chose effect sizes to be 0.5, 0.6, and 0.7.
False discovery rate (FDR) was controlled at 0.05 for each method, and each simulation was
repeated 200 times. The details of simulation settings are described in Table 4.
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Table 4: Settings of simulation scenario
Study1 Study 2 Study 3
Effect size N (n11, n12, n13) = (10, 5, 8) (n21, n22, n23) = (5, 8, 10) (n31, n32, n33) = (8, 10, 5)
(µ11, µ12, µ13), σ1 (µ21, µ22, µ23), σ2 (µ31, µ32, µ33), σ3
0.5 I (1,3,5),3.5 (2,4,6),3.1 (1,4,7),4.4
II (1,3,5),3.5 (6,4,2),3.1 (1,7,1),5.9
III (1,3,5),3.5 (6,4,2),3.1 (0,0,0),5.3
Null (0,0,0),3.5 (0,0,0),3.1 (0,0,0),4.4
0.6 I (1,3,5),2.9 (2,4,6),2.6 (1,4,7),3.7
II (1,3,5),2.9 (6,4,2),2.6 (1,7,1),4.8
III (1,3,5),2.9 (6,4,2),2.6 (0,0,0),4.4
Null (0,0,0),2.9 (0,0,0),2.6 (0,0,0),3.7
0.7 I (1,3,5),2.5 (2,4,6),2.2 (1,4,7),3.2
II (1,3,5),2.5 (6,4,2),2.2 (1,7,1),4.3
III (1,3,5),2.5 (6,4,2),2.2 (0,0,0),3.8
Null (0,0,0),2.5 (0,0,0),2.2 (0,0,0),3.2
I: Genes with concordant patterns across studies. The mean vector in Study 1 is (1,3,5)
which has the same pattern (trend) as the mean vector, (2,4,6), in Study 2 and (1,4,7)
in Study 3.
II: Genes with discordant patterns across studies. The mean vector in Study 1 is (1,3,5)
which has the different pattern (trend) from the mean vector, (6,4,2), in Study 2 and
(1,7,1) in Study 3.
III: Genes with concordant patterns in study 1 and study 2 but no pattern in study 3. The
mean vector for Study 1 is (1,3,5), (6,4,2) for Study 2 and (0,0,0) for Study 3.
Null: Null genes.Do not have any pattern in the studies.
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The average numbers of genes identified in each category by the three methods (ANOVA-
maxP, min-MCC and OW-min-MCC) under each simulation scenario is presented in Table
2. We note that each of the three methods has specific target of biomarkers: ANOVA-maxP
detects concordant and discordant biomarkers across all three studies (i.e. category I and
II); min-MCC identifies concordant biomarkers across all three studies (i.e. category I); OW-
min-MCC finds concordant biomarkers across two or more studies (i.e. category I and III).
Thus, we define three types of false discov-ery rates for the corresponding biological purposes:
FDR1=(III+null)/(I+II+III+null) for ANOVA-maxP, FDR2=(II+III+null)/(I+II+III+null)
for min-MCC and FDR3=(II+null)/(I+II+III+null) for OW-min-MCC.
As expected, ANOVA-maxP detects both category I and cate-gory II genes because the
p-values in ANOVA do not reflect the inter-class pattern information for each individual
study. On the other hand, min-MCC method detects almost only concordant inter-class
genes (category I). For example, when effect size equals 0.6, min-MCC detects an average of
260.52 (out of 300) genes of true concordant inter-class pattern genes, while ANOVA-maxP
only identifies 193.11 concordant genes together with 73.5 discordant biomarkers. Both of
ANOVA-maxP and min-MCC detect few bio-markers of category III because genes in cate-
gory III are differen-tially expressed only in study 1 and 2 but not in study 3. OW-min-MCC
detects biomarkers mostly in category I and III but not in II since it is designed to detect
concordant biomarkers in two or more studies. The simulation result clearly confirms that
selection among the three methods depend on the ultimate biological purpose.
Result of the FDR calculation reveals an interesting issue of our proposed algorithm.
FDR3 for OW-min-MCC is controlled near the nominal FDR=5%. FDR1 and FDR2 are,
however, anti-conservative. This is an issue of HSA that the null hypothesis is essentially
a composite null hypothesis, instead of a simple null hypothesis. We will discuss further in
the ”Conclusion Section”.
57
Table 5: Results of simulation scenario
Effect size Methods I II III Null FDR1(%) FDR2(%) FDR(%)
0.5 ANOVA-maxP 107.08 44.23 7.56 5.22 7.8a 34.7 30.1
min-MCC 197.42 0.22 10.05 7.95 8.3 8.4b 3.8
OW-min-MCC 163.67 3.76 29.74 5.23 17.3 19.1 4.4c
0.6 ANOVA-maxP 193.11 73.50 13.47 9.45 7.9a 33.3 28.6
min-MCC 260.52 0.05 15.56 10.85 9.2 9.2b 3.8
OW-min-MCC 253.19 7.10 57.98 8.73 20.4 22.6 4.8c
0.7 ANOVA-maxP 250.77 88.98 16.26 11.63 7.6a 31.8 27.4
min-MCC 287.97 0.03 19.24 11.96 9.8 9.8b 3.8
OW-min-MCC 288.54 9.74 80.41 10.15 23.3 25.8 5.1c
I: genes with concordant patterns across studies.
II: genes with discordant patterns across studies.
III: genes with concordant patterns in study 1 and study 2 but no pattern in study 3.
Null: Null genes.
a: ANOVA-maxP detects both concordant and discordant genes (category I and II). FDR1
(= III+Null
I+II+III+Null
) is a better measure for false discoveries.
b: Min-MCC detects only concordant genes (category I). FDR2 (= II+III+Null
I+II+III+Null
) is a better
measure for false discoveries.
c: OW-min-MCC detects category I and III genes only. FDR3 (= II+Null
I+II+III+Null
) is a better
measure for false discoveries.
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3.4.2 Data description
Mouse Metabolism Data
Three real data sets are used to evaluate proposed methods. The first data set involves
samples from three genotype mice: wild-type (WT), LCAD knock-out (LCAD -/-) and
VLCAD knock-out (VLCAD -/-). Deficiency of very long chain acyl-CoA dehydrogenase
(VLCAD) is known to be related to a common energy metabolism disorder in children.
On the other hand, LCAD (long-chain acyl-CoA dehydrogenase) deficient mice are known
to have impaired fatty acid oxidation and develop a disease similar to other disorders of
mitochondrial fatty acid oxidation. For each of the 12 mice (four mice in each genotype),
four types of tissues (brown fat, skeletal, liver and heart) were applied to the microarray
experiment separately to study the expression changes across genotypes. For duplicate spots,
mean of them were used. Data from the four tissues were combined and log2 transformed.
Genes with little information content (average log2-scaled means < 7 or average log2-scaled
standard deviations < 0.4) are filtered out. A total of 4,288 genes are left for meta-analysis.
Among the 48 arrays performed, four arrays were identified with quality defect and were
deleted from further analysis. The detailed sample information is described in Table 6.
Table 6: Mouse metabolism data
tissue type brown fat liver heart skeletal Total
genotype WT V- L- WT V- L- WT V- L- WT V- L-
n of arrays 4 4 4 4 4 4 3 4 4 3 3 3 44
WT: wilde type; V-:VLCAD -/-; L-:LCAD -/-
Mouse Trauma Data
The second data set applied is about mouse trauma experiments. Victims of trauma-
hemorrhagic shock (T-HS) (for example those due to car accident etc) often die due to severe,
complex and uncontrollable physiological disturbances that occur in many organs, especially
the liver. The progress of T-HS and resuscitation (R) is examined by well-controlled murine
systems to identify gene expression profiles that are characteristic of this stress. Specifically
five groups of mice experiments were performed: (I) non-manipulated mice to serve as the
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negative control group; (II) 1.5h of Hemorrhagic Shock without resuscitation (1.5hHS) served
as the positive control group; (III) 1.5h of hemorrhagic shock + bone fracture, followed by
one hour of fluid resuscitation (1.5hHS+BF+1hR); (IV) Similar to group III except for 4.5h
of fluid resuscitation (1.5hHS+BF+4.5hR); (V) Similar to group III except for 6h of fluid
resuscitation (1.5hHS+BF+6hR). Four mice are performed in each group with the liver sam-
ples applied to microarray experiments (a total of 20 mice). The array experiments are done
twice by both Codelink and Affymetrix platforms. One array of group II in Codelink and
one array of group II in Affymetrix had problematic quality and were removed from further
analysis. Table 7 describes the experimental details of the multi-platform data. After some
standard preprocessing procedures, 19,132 genes from Affymetrix platform and 26,063 genes
from Codelink platform were matched by GeneCruiser, resulting in 6,338 common genes for
the meta-analysis.
Table 7: Mouse trauma data
array platform Codlink Affymetrix Total
experimental conditions I II III IV V I II III IV V
number of arrays 4 3 4 4 4 4 3 4 4 4 38
I: No manipulation; II: 1.5h HS; III: 1.5h HS+BF+1h R; IV: 1.5h HS+BF+4.5h R;
V: 1.5h HS+BF+6h R.
Prostate Cancer Data
The third data is prostate cancer data from three different data sets, Dha-nasekaran et
al (2001), Lapointe et al ( 2004), and Varambally et al (2005). These three data sets
all have three tumor types, normal, tumor, and meta-static. Data from the three studies
were log2 transformed and converted to Entrez ID for combining with other studies. Genes
with large missing percentage (means > 40 %) or little information content (average log2-
scaled means < 7 or average log2-scaled standard deviations < 0.4) are filtered out. KNN
imputation method was used for the missing values before applying proposed methods. The
basic experimental information is in Table 8.
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Table 8: Sample description of three prostate cancer studies
Dhanasekaran Lapointe Varambally
Array type cDNA cDNA Affy HU133Plus2
Tissue type N T M N T M N T M
N of arrays 14 13 20 41 62 9 6 7 6
N: Normal; T: Tumor; M: Metastasis
The first data set contains a multi-tissue design. The application of HSA helps to detect
tissue-specific biomarkers and HSB identifies consistent tissue-invariant biomarkers. Both
hypothesis settings are of biological interest. On the other hand, the second data set con-
tains a multi-platform design. HSB is of interest to generate highly confident biomarkers
confirmed by both platforms while HSA becomes of less biological interests. The detected
platform-specific biomarkers from HSA may help to identify technical issues across the two
platforms.
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3.4.3 Application to mouse metabolism data
We first applied ANOVA-maxP and min-MCC methods to the mouse metabolism data. For
the first biological goal, we were interested in genes with clear inter-class patterns but may
be discordant across tissues. These tissue-dependent biomarkers reflected tissue-specific bi-
ological changes under VLCAD and LCAD mutations.
ANOVA-maxP identified 637 genes and the heatmap of detected biomarkers is shown in
the left plot of Figure 7A. Figure 7B shows a histogram of min-MCC (minimum of pair-wise
multi-class correlation measures across four tissues) of the 637 detected biomarkers. 408 of
the 637 genes (64.05%) had negative min-MCC (i.e. with discordant inter-class patterns in
at least a pair of tissues). The right panel of Figure 7A shows the heatmap of these 408
discordant genes and the heatmap of 229 genes with positive min-MCC. The genes with dis-
cordant patterns are potential targets to identify tissue-specific regulators in the mutations.
The second biological goal was to identify biomarkers that have consistent inter-class
pattern across all four tissues (i.e. reliable tissue-invariant biomarkers). To achieve this
goal, min-MCC served better for this purpose. A total of 387 genes were identified and are
displayed in Figure 7C. It is clearly seen that these genes have clear concordant inter-class
pat-terns across all four tissues. A simple cluster analysis can further group them into six
major patterns for further biological investigation. A manuscript of this on-going project
containing detailed bio-logical discoveries is under preparation.
Finally, we applied OW-min-MCC method to allow detection of concordant biomarkers
in partial (two or more) studies. Table 8 shows all 11 possible categories of the weights and
the number and percentage of detected biomarkers. Among the 1,209 biomarkers detected
by OW-min-MCC, we found that the number of significant biomarkers is relatively small
(398) when the optimal weights included skeletal while heart involved the highest number
of bio-markers (960). Heatmap of the 1,209 biomarkers is shown in Figure 8.
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Figure 7: Heatmap of significant genes detected in mouse metabolism data.
A(Left): heatmap of 637 ANOVA-maxP genes, A(Right): heatmap of discordant ANOVA-
maxP genes and concordant ANOVA-maxP genes. B: histogram of min-MCC of the 637
ANOVA-maxP genes, C: heatmap of 387 min-MCC genes (B: Brown fat; L: Liver; H: Heart;
S: Skeletal muscle. 1: Wild type; 2: VLCAD -/-; 3: LCAD -/-.)
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Table 9: OW-min-MCC results for mouse metabolism data
Category Weight Tissue number of sig. genes %
1 (1,1,0,0) Brown, Liver 126 10.42
2 (1,0,1,0) Brown, Heart 258 21.34
3 (1,0,0,1) Brown, Skeletal 31 2.56
4 (0,1,1,0) Liver, Heart 240 19.85
5 (0,1,0,1) Liver, Skeletal 54 4.47
6 (0,0,1,1) Heart, Skeletal 98 8.11
7 (1,1,1,0) Brown, Liver, Heart 187 15.47
8 (1,1,0,1) Brown, Liver, Skeletal 38 3.41
9 (1,0,1,1) Brown, Heart, Skeletal 75 6.20
10 (0,1,1,1) Liver, Heart, Skeletal 53 4.38
11 (1,1,1,1) Brown, Heart, Live, Skeletal 49 4.05
Total 1209 100
Brown: Categories including: 1, 2, 3, 7, 8, 9, 11; Total number of biomarkers: 764.
Liver: Categories including: 1, 4, 5, 7, 10, 11; Total number of biomarkers: 747.
Heart: Categories including: 2, 4, 6, 7, 9, 10, 11; Total number of biomarkers: 960.
Skeletal: Categories including: 3, 5, 6, 8, 9, 10, 11; Total number of biomarkers: 398.
The number of significant biomarkers is relatively small when the weight included Skele-
tal. It could give us some information that genes could have different expression levels in
Skeletal.
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Figure 8: Heatmap for OW-min-MCC.
Heatmap of significant biomarkers for these 11 categories of weights. (wt: Wild Type, V-:
VLCAD-/-, L-: LCAD-/-)
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3.4.4 Application to mouse trauma data
We similarly applied ANOVA-maxP and min-MCC to the mouse trauma data. We did not
apply OW-min-MCC since there were only two studies (platforms). We note that the two
studies to be combined were from two commercial platforms, Affymetrix and Codelink. Ide-
ally both array platforms measure identical samples and there should exist no discordant
biomarkers. Combining the two data sets should increase statistical power and detect more
concordant inter-class pattern genes.
Indeed, by controlling FDR at 0.05, ANOVA-maxP detected 3388 genes (heatmap shown
in the left plot of Figure 9A) and 179 (5.28%) genes showed discordant inter-class patterns
of negative MCC across the two platforms (right plot of Figure 9A). Figure 9B shows the
histogram of min-MCC of the 3388 ANOVA-maxP genes. On the other hand, 3633 genes
were identified using min-MCC (figure 9C). These highlyreliable biomarkers confirmed by
both platforms were used for further cluster analysis and pathway analysis to understand
the biological changes under different severity of trauma (manuscript in preparation).
The higher proportion of genes with concordant inter-class patterns confirmed that the
two array platforms are highly reproducible. The 179 discordant inter-class pattern genes
are, however, technical errors and need further investigation. The discordances are possibly
due to mistaken gene annotation, differential hybridization efficiencies caused by different
probe selection criteria or non-specific cross-hybridization.
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Figure 9: Heatmap of significant genes in mouse trauma data.
A(Left): heatmap of 3388 ANOVA-maxP genes, A(Right): heatmap of 3209 concordant
ANOVA-maxP genes and 179 discordant ANOVA-maxP genes. B: histogram of min-MCC
of the 3388 ANOVA-maxP genes, C: heatmap of 3633 min-MCC genes.
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3.4.5 Application to prostate cancer data
We applied ANOVA-maxP and min-MCC to three prostate cancer studies (Dhanasekaran,
Lapointe, and Varambally) that investigated three classes of normal, localized tumor and
metastatic tumor tissues. After filtering and merging these three data sets, we obtained
1,004 genes for downstream analysis.
Among these 1,004 genes, ANOVA-maxP detected 206 biomarkers, and min-MCC iden-
tified 120 biomarkers. We performed pathway analysis using Ingenuity Pathway Analy-
sis (IPA) software to investigate which biological functions are related (enriched) in the
biomarker lists. The top p-values of enrichment analysis without multiple comparison cor-
rection are presented in Table 10. In these 56 cancer-related biological functions, p-values of
min-MCC are always much more significant than those from ANOVA-maxP.
In this application, ANOVA-maxP clearly adds in biomarkers of discordant patterns that
are likely to be false positives. The result of min-MCC provides a better biomarker list to
investigate the biological process from normal to localized tumors and to further malignant
metastatic tumors.
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Table 10: IPA biological functions results for prostate cancers.
Category min-MCC∗ ANOVA-maxP∗ N1 N2 N3
Cardiovascular Disease 0.000885 0.029 5 9 1
Cell Death 0.000885 0.0419 4 2 0
Dermatological Diseases 0.000885 0.0419 10 2 0
Cellular Development 0.00167 0.0419 6 2 1
Skeletal and Muscular System 0.00167 0.0419 3 2 0
Tissue Development 0.00167 0.0419 17 6 0
Nervous System Development 0.00167 >0.05 12 0 0
Respiratory Disease 0.00167 >0.05 5 0 0
Cellular Movement 0.00266 >0.05 10 0 0
∗: enrichment p-value.
N1: number of biomarkers for min-MCC;
N2: number of biomarkers for ANOVA-maxP;
N3: number of intersection.
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4.2 FUTURE WORK
There are some works we can put effort on in the future.
1. Missing values pose another issue in merging multiple studies. For instance, if we just
select the genes which exist among all the studies, a small set of genes could be gained
and a lot of information lost which in turn has an adverse impact on ensuing analyses. On
the other hand, if we target a certain percentage of existence of the genes, say 80% which
means 20% of the values are allowed to be missing, this can give us more information for
the meta-analysis. We are searching for a reasonable percentage of missing values and are
investigating the influence on the analysis.
2. In addition to the issue of combining multiple studies, there are a few possible exten-
sions and future directions. Currently we consider all studies to have identical K classes. Both
ANOVA-maxP and min-MCC can be extended to studies containing mismatched classes of
different sizes. For example, for min-MCC, the pairwise MCC can be defined using only the
overlapping classes across a pair of studies. If we have three studies as following:
Study 1 2 3
class A B C D A B C D E B C D
Let MCC1 be the pairwise MCC of Study 1 and Study 2 for the overlapping classes (A, B,
C, D), MCC2 be the pairwise MCC of Study 1 and Study 3 for the overlapping classes (B,
C, D) and MCC3 be the pairwise MCC of Study 2 and Study 3 for the overlapping classes
(B, C, D). Then, the min-MCC for these three studies is min1≤i≤3MCCi.
3. These three proposed methods utilize the most conservative and extreme statistic
(maximum of ANOVA p-values and minimum of pairwise MCC). This may be too stringent
and sensitive to outliers, especially when the class, K, is large. A quick modification may be
to use the rth ranked statistic instead.
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4. The biological meanings and functions of these detected biomarkers are of interest.
Gene Ontology (GO) enrichment analyses can be conducted to investigate the biological
pathways and knowledge of these detected biomarkers. Gene cluster analysis is another po-
tentially effective strategy to further investigate the deteced biomarkers.
5. Developing a hierarchical meta-analysis method, as 4.1 shows, to investigate the genes’
behavior not only across different studies, but also across different types of cancers is also of
interest.
Cancer Types︷ ︸︸ ︷
Breast︷ ︸︸ ︷
S1 . . . Sn1
Leukemia︷ ︸︸ ︷
S1 . . . Sn2
Lung︷ ︸︸ ︷
S1 . . . Sn3
Prostate︷ ︸︸ ︷
S1 . . . Sn4 (4.1)
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APPENDIX 
 
A.1  CANCER STUDIES 
 
 
 
 
 
 
 
Cancer Type Author Year Array Type 
Prostate cancer Dhanasekaran 2001 cDNA 
 Luo 2001 cDNA 
 Magee 2001 Aﬀy HG6800 
 Welsh 2001 Aﬀy HU95A 
 Ernst 2002 Aﬀy HU95A 
 Luo 2002 Aﬀy HU95A 
 Singh 2002 Aﬀy HU95Av2 
 Henshall 2003 Aﬀy Eos Hu03 
 Chen 2004 Aﬀy HU95Av2 
 Lapointe 2004 cDNA 
 Stuart 2004 Aﬀy HU95Av2 
 Yu 2004 Aﬀy HU95A 
 Best 2005 Aﬀy HU133A 
 Varambally 2005 Aﬀy HU133 
 Nanni 2006 Aﬀy Hu133A 
 Tomlins 2007 cDNA 
Lung cancer Bhattacharjee 2001 (Harvard) Aﬀy HU95A 
 Garber 2001 (Stanford) cDNA 
 Beer 2002 (Michigan) Aﬀy HG6800 
 Gordon 2002 Aﬀy HU95A 
 Wigle 2002 cDNA 
 Michael 2004 cDNA 
 Magda 2005 Aﬀy HU133A 
 Washi 2005 Aﬀy HU133A 
 Gemma 2006 Aﬀy HU133A 
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Cancer Type Author Year Array Type
Breast cancer Perou 1999 cDNA
Perou 2000 cDNA
Sorlie 2001 cDNA
vant Veer 2002 cDNA
Chang 2003 Affy HU95Av2
Sorlie 2003 cDNA
Sotiriou 2003 cDNA
Acevedo 2004 Affy HU133A
Frasor 2004 Affy HU95A
Ma 2004 Agilent
Troester 2004 cDNA
Farmer 2005 Affy HU133A
Moggs 2005 Affy HU133A
Rouzie 2005 Affy HU133A
Yang 2005 Affy HU133A
Bild 2006 Affy HU95A
Colon cancer Alon 1999 Affy HU6800
Agrawal 2002 Affy HU95A
Fleet 2003 Affy HU95A
Anderle 2004 Affy HU133A
Bertucci 2004 Affy
Bertucci 2004 Affy
Bandres 2005 Affy
Barrier 2005 Affy HU133A
Dommels 2005 Affy
West 2005 Affy HU133Plus2
Koinuma 2006 Affy HU133A
Whitney 2006 Affy HU133
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Cancer Type Author Year Array Type
Leukemia cancer Cheok 2003 Affy HU95A
Yagi 2003 Affy HU95A
Addya 2004 Affy HU133A
Haslinger 2004 Affy HU95A
Scandura 2004 Affy HU133A
Stegmaier 2004 Affy HU133A
Crossman 2005 Affy HU95A
Depitta 2005 cDNA
Dik 2005 Affy HU133A
Falt 2005 Affy HU95
Gutierrez 2005 Affy HU133A
Neumann 2005 Affy HU-Focus
Raetz 2006 Affy HU133A
A.2 INTERQUARTILE RANGE, IQR
In descriptive statistics, the interquartile range (IQR), also called the midspread, middle
fifty and middle of the number of observations, is a measure of statistical dispersion, being
equal to the difference between the third and first quartiles.
Unlike the (total) range, the interquartile range is a robust statistic, having a breakdown
point of 25%, and is thus often preferred to the total range. The IQR is used to build box
plots, simple graphical representations of a probability distribution.
For a symmetric distribution (so the median equals the midhinge, the average of the first
and third quartiles), half the IQR equals the median absolute deviation (MAD). The median
is the corresponding measure of central tendency.
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Figure 10: Interquartile range (IQR).
Boxplot (with an interquartile range) and a probability density function (pdf) of a Normal
N(0,σ2) Population
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